Hybridon, Inc.

Adrienne P Smyth

Gregory S Robinson

Disclosed are oligonucleotides complementary to VEGF-specific nucleic acid useful in reducing the expression of VEGF. Also disclosed are pharmaceutical formulations containing such oligonucleotides useful for treating various disorders associated with neovascularization and angiogenesis.

Modified VEGF Oligonucleotides for Inhibition of tumor growth

Disclosed are oligonucleotides complementary to VEGF-specific nucleic acid useful in reducing the expression of VEGF. Also disclosed are pharmaceutical formulations containing such oligonucleotides useful for treating various disorders associated with neovascularization and angiogenesis, and methods for treating psoriasis.

Modified VEGF oligonucleotides for treatment of skin disorders

Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to at least a portion of the multi-drug resistant-1 gene, or transcripts thereof, which portion encodes a nucleoside binding site. Also disclosed is a pharmaceutical formulation containing such oligonucleotides, and methods of treating multidrug resistant cancer cells, of preventing the expression of P170 in a cell, and of preventing the induction of multidrug resistance in a cancer cell.

Growing community of inventors

Charlton, MA, United States of America

Adrienne P Smyth